{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:05:08Z","timestamp":1789621508744,"version":"build-2803163510"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Achondroplasia is the most common skeletal dysplasia and presents as a lifelong, multi-system condition characterized by disproportionate short stature, rhizomelic limb shortening, macrocephaly with frontal bossing, and a spectrum of neurological, respiratory, orthopedic, and psychosocial complications. Effective management requires anticipatory surveillance, coordinated multidisciplinary care, and early recognition of life-threatening complications. Therapeutic options have expanded in recent years with the introduction of vosoritide, a C-type natriuretic peptide analog that targets the underlying pathophysiology and has demonstrated significant improvements in linear growth and body proportionality in eligible children. However, global advances have not been uniformly translated into clinical practice across the Middle East, where challenges such as delayed diagnosis, inconsistent access to genetic testing, limited multidisciplinary infrastructure, and inequities in treatment availability continue to impact patient outcomes. In this document, a panel of pediatric endocrinologists and clinical geneticists from the Middle East convened to develop a set of regionally relevant, evidence-informed consensus statements on the diagnosis and management of achondroplasia in light of novel advances in the management of this condition. Using a modified Delphi process, the panel achieved consensus on 25 statements covering diagnosis, surveillance, multidisciplinary management, psychosocial support, pharmacologic interventions, transition to adult care, and research priorities. This consensus, endorsed by the Arab Society for Pediatric Endocrinology and Diabetes (ASPED) and the MENA Medical Genetics Association, aims to standardize and enhance the quality of care for individuals with achondroplasia across the region by integrating international best practices with local healthcare realities. The author panel believes that the implementation of these recommendations has the potential to improve early detection, optimize long-term outcomes, strengthen family support, and expand equitable access to emerging therapies.<\/jats:p>","DOI":"10.3389\/fendo.2026.1888346","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:50:11Z","timestamp":1789620611000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Consensus statement on the management of Achondroplasia in the Middle East"],"prefix":"10.3389","volume":"17","author":[{"given":"Nandu","family":"Thalange","sequence":"first","affiliation":[{"name":"Pediatric Endocrinologist, Genesis Healthcare","place":["Dubai, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawfeg","family":"Ben Omran","sequence":"additional","affiliation":[{"name":"Medical Geneticist, Sidra Medicine","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afaf","family":"Alsagheir","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinologist, King Faisal Specialist Hospital & Research Centre","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Hussain","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinologist, Sidra Medicine","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Faden","sequence":"additional","affiliation":[{"name":"Medical Geneticist and Metabolic Specialist, King Saud Medical City","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Aglan","sequence":"additional","affiliation":[{"name":"Professor of Clinical Genetics, National Research Centre","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sareea","family":"Alremeithi","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinologist, Sheikh Khalifa Medical City","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelhadi","family":"Habeb","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinologist, National Guard Hospital","place":["Madinah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s13023-021-01971-6","article-title":"The first European consensus on principles of management for achondroplasia","volume":"16","author":"Cormier-Daire","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2022.08.015","article-title":"Growth parameters in children with achondroplasia: A 7-year, prospective, multinational, observational study","volume":"24","author":"Savarirayan","year":"2022","journal-title":"Genet Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.61787","article-title":"Birth prevalence of achondroplasia: A systematic literature review and meta-analysis","volume":"182","author":"Foreman","year":"2020","journal-title":"Am J Med Genet A"},{"key":"B4","volume-title":"Achondroplasia","author":"Chamarthi","year":"2025"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0972-6","article-title":"Achondroplasia: a comprehensive clinical review","volume":"14","author":"Pauli","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/s12887-022-03505-w","article-title":"Achondroplasia in Latin America: practical recommendations for the multidisciplinary care of pediatric patients","volume":"22","author":"Llerena","year":"2022","journal-title":"BMC Pediatr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/dvdy.24479","article-title":"Achondroplasia: Development, pathogenesis, and therapy","volume":"246","author":"Ornitz","year":"2017","journal-title":"Dev Dyn"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.115872","article-title":"Lifetime impact of achondroplasia: Current evidence and perspectives on the natural history","volume":"146","author":"Hoover-Fong","year":"2021","journal-title":"Bone"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/09638288.2021.1963853","article-title":"Quality of life, physical functioning, and psychosocial function among patients with achondroplasia: a targeted literature review","volume":"44","author":"Constantinides","year":"2022","journal-title":"Disabil Rehabil"},{"key":"B10","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1159\/000543743","article-title":"Real-world safety and effectiveness of vosoritide in children with achondroplasia: french early access program","volume":"99","author":"Cormier-Daire","year":"2025","journal-title":"Horm Res Paediatr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"100566","DOI":"10.2139\/ssrn.4918018","article-title":"Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study","volume":"6","author":"Savarirayan","year":"2025","journal-title":"Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s12325-023-02705-9","article-title":"Vosoritide therapy in children with achondroplasia: early experience and practical considerations for clinical practice","volume":"41","author":"Semler","year":"2024","journal-title":"Adv Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/2042018820904016","article-title":"New perspectives on the treatment of skeletal dysplasia","volume":"11","author":"Marzin","year":"2020","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.16290","article-title":"Australian guidelines for the management of children with achondroplasia","volume":"59","author":"Tofts","year":"2023","journal-title":"J Paediatr Child Health"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00595-x","article-title":"International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia","volume":"18","author":"Savarirayan","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2020-319625","article-title":"Achondroplasia Foramen Magnum Score: screening infants for stenosis","volume":"106","author":"Cheung","year":"2021","journal-title":"Arch Dis Child"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-018-0070-0","article-title":"Cervical spinal cord compression in infants with achondroplasia: should neuroimaging be routine","volume":"21","author":"Sanders","year":"2019","journal-title":"Genet Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1297\/cpe.29.25","article-title":"Clinical practice guidelines for achondroplasia","volume":"29","author":"Kubota","year":"2020","journal-title":"Clin Pediatr Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/children11070789","article-title":"Consensus guidelines for the use of vosoritide in children with achondroplasia in Australia","volume":"11","author":"Tofts","year":"2024","journal-title":"Children (Basel)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13023-021-01678-8","article-title":"Best practice guidelines in managing the craniofacial aspects of skeletal dysplasia","volume":"16","author":"Savarirayan","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-1010","article-title":"Health supervision for people with achondroplasia","volume":"145","author":"Hoover-Fong","year":"2020","journal-title":"Pediatrics"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02549-3","article-title":"Burden and treatment of achondroplasia: A systematic literature review","volume":"40","author":"Murton","year":"2023","journal-title":"Adv Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.61974","article-title":"Clinical charts for surveillance of growth and body proportion development in achondroplasia and examples of their use","volume":"185","author":"Neumeyer","year":"2021","journal-title":"Am J Med Genet A"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-03061-y","article-title":"Considerations for anthropometry specific to people with disproportionate short stature","volume":"42","author":"Hoover-Fong","year":"2025","journal-title":"Adv Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf041","article-title":"Real-world outcome of vosoritide treatment in children with achondroplasia: A 12-month retrospective observational study","volume":"9","author":"Reincke","year":"2025","journal-title":"J Endocr Soc"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03223-6","article-title":"Real-world safety and effectiveness of vosoritide in achondroplasia: results from a single center in Portugal","volume":"42","author":"Rua","year":"2025","journal-title":"Adv Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-024-01074-9","article-title":"International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia","volume":"21","author":"Savarirayan","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/s2352-4642(23)00265-1","article-title":"Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"8","author":"Savarirayan","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.87983","article-title":"Vosoritide (Voxzogo) for achondroplasia: A review of clinical and real-world evidence","volume":"17","author":"Jones","year":"2025","journal-title":"Cureus"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2024-rcpch.356","article-title":"6532\u2005Safety and efficacy of vosoritide in patients with achondroplasia- a systematic review","volume":"109","author":"Shouli","year":"2024","journal-title":"Arch Dis Childhood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13256-025-05231-0","article-title":"Hypertrichosis associated with the use of C-type natriuretic peptide analogue: a case report","volume":"19","author":"Clinton","year":"2025","journal-title":"J Med Case Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s12020-024-03938-6","article-title":"A comprehensive systematic review of health-related quality of life measures in short stature paediatric patients","volume":"86","author":"Adedeji","year":"2024","journal-title":"Endocrine"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/cge.13542","article-title":"Current knowledge of medical complications in adults with achondroplasia: A scoping review","volume":"97","author":"Fredwall","year":"2020","journal-title":"Clin Genet"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1888346\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:50:15Z","timestamp":1789620615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1888346\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":33,"alternative-id":["10.3389\/fendo.2026.1888346"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1888346","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"1888346"}}